Japan’s Takeda Gets Mixed Results For DPP-4 Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Data from trials of Takeda Pharmaceutical's SYR-322 (alogliptin) for treating diabetes show mixed results for the DPP-4 inhibitor. Set to be reported at the annual meeting of the American Diabetes Association, the data are expected to show that although the drug is effective enough to gain approval, it may not be an improvement over Merck's Januvia (sitagliptin phosphate), the only other marketed DPP-4 drug. The success of Takeda's version is considered crucial because it loses patent protection in three years for its $3 billion-a-year Actos (pioglitazone hydrochloride) diabetes drug. (Click here for more